Iron Chelation in the Prevention of Secondary Degeneration After Stroke
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Stroke is a major cause of disability over the world. While acute therapies have made huge
progresses, the number of survivors leaving with clinical consequences of stroke is
increasing. Beyond stroke itself, secondary neurodegeneration of disconnected areas,
especially of central hubs such as the substantia nigra or the thalamus, could significantly
impact the overall outcome of the patients. Data from our group and others have identified
iron accumulation within the disconnected areas as potentially accelerating
neurodegeneration. In this research, the main objective is test whether long-term chelation
through Deferiprone (Ferrirpox®, Chiesi) administered daily from 3-to-5 days following stroke
to 6 months could avoid iron accumulation as measured with Magnetic resonance imaging (MRI)
within disconnected areas (substantia nigra).
MRI imaging methods such as the quantification of the transverse relaxation rate R2* provide
highly correlated information to the histologically measured iron load